Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
The purpose of this study is to determine whether sulindac and VSL#3 - inulin, either combined or alone, are effective in treating or preventing adenoma development in the ileal anal pouch in patients with familial adenomatous polyposis.
Adenomatous Polyposis Coli
DRUG: Sulindac (drug)|DRUG: VSL#3 (probiotic)|DRUG: Inulin (probiotic)
Pouch mucosal proliferation index at 0, 1 and 2 months|Pouch mucosal apoptosis index at 0, 1 and 2 months
Pouch mucosal Glutathione S transferases activity and isoenzyme levels at 0, 1 and 2 months|Faecal genotoxicity at 0, 1 and 2 months|Faecal cytotoxicity at 0, 1 and 2 months
The purpose of this study is to determine whether sulindac and VSL#3 - inulin, either combined or alone, are effective in treating or preventing adenoma development in the ileal anal pouch in patients with familial adenomatous polyposis.